Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6129754 | Clinical Microbiology and Infection | 2015 | 10 Pages |
Abstract
In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3Â ng/mL (interquartile range 43-58Â ng/mL); in others, it was significantly (p 0.019) higher: 151Â ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
L. Boglione, A. De Nicolò, C.S. Cardellino, T. Ruggiero, V. Ghisetti, G. Cariti, G. Di Perri, A. D'Avolio,